US › Healthcare

Oramed Pharmaceuticals Inc (ORMP)

US · Healthcare · Biotechnology

$4.67+1.08%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$78.2M

Profit YoY

+488.2%

EPS

$-0.09

EPS estimate

$0.43

EPS came in at -0.09 against a street estimate of 0.43 — a miss of 120.9%.

Key statistics

Market cap

$193.8M

P/E

1.1

Forward P/E

0.0

P/B

0.61

Book value

$7.68

EPS (TTM)

$4.13

52-week high

$5.47

52-week low

$1.95

50-day MA

$4.47

200-day MA

$3.78

Beta

1.19

Analyst view

Analysts rate Oramed Pharmaceuticals Inc a hold (0 buy, 1 hold, 0 sell out of 1) with an average price target of $7.00.

Shareholding

Insiders

17.65%

Institutions

45.11%

Largest institutional holders

Fund	Stake
Aquamarine Financial (Cayman) Ltd	6.04%
Gem Investment Advisors, LLC	4.81%
Mercer Global Advisors Inc.	4.59%
Murchinson Ltd.	3.16%
BML Capital Management LLC	2.08%
BOOTHBAY FUND MANAGEMENT, LLC	1.44%
Marshall Wace Asset Management Ltd	0.62%
Rathbone Brothers PLC	0.56%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Oramed Pharmaceuticals Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.